Innate Pharma to Participate in Upcoming Investor Conferences
January 04, 2021 01:00 ET
|
INNATE PHARMA
MARSEILLE, France, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior...
Innate Pharma retourne les droits de commercialisation de Lumoxiti aux Etats-Unis et en Europe à AstraZeneca
December 11, 2020 01:00 ET
|
INNATE PHARMA
Marseille, 11 déc. 2020 (GLOBE NEWSWIRE) -- Innate ne poursuivra pas les activités de commercialisation de Lumoxiti aux Etats-Unis et en Europe ; la Société recentre ses investissements sur son...
Innate Pharma to return US and EU Lumoxiti commercialization rights to AstraZeneca
December 11, 2020 01:00 ET
|
INNATE PHARMA
Marseille, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Innate will no longer pursue Lumoxiti commercialization activities in US or EU; Company to re-focus investments in its R&D portfolio Companies...
Innate Pharma to Return US and EU Lumoxiti Commercialization Rights to AstraZeneca
December 11, 2020 01:00 ET
|
INNATE PHARMA
Innate will no longer pursue Lumoxiti commercialization activities in US or EU; Company to re-focus investments in its R&D portfolio Companies will develop a transition plan with the goal of...
Innate Pharma présentera des données additionnelles d'efficacité pour monalizumab en combinaison avec cetuximab dans les cancers tête et cou au congrès virtuel de l'ESMO immuno-oncologie
December 03, 2020 08:30 ET
|
INNATE PHARMA
Marseille, 03 déc. 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris : IPH – ISIN : FR0010331421 ; Nasdaq : IPHA) (« Innate » ou la « Société ») a annoncé aujourd’hui que des données...
Innate Pharma to present additional efficacy data for monalizumab in combination with cetuximab in head and neck cancer at the ESMO immuno-oncology virtual congress
December 03, 2020 08:30 ET
|
INNATE PHARMA
Marseille, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will present additional...
Innate Pharma to Present Additional Efficacy Data for Monalizumab in Combination With Cetuximab in Head and Neck Cancer at the ESMO Immuno-Oncology Virtual Congress
December 03, 2020 08:30 ET
|
INNATE PHARMA
MARSEILLE, France, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will present...
Innate Pharma publie son calendrier financier pour 2021
December 02, 2020 01:00 ET
|
INNATE PHARMA
Marseille, 02 déc. 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris : FR0010331421 – IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») publie aujourd’hui son calendrier financier...
Innate Pharma 2021 financial calendar
December 02, 2020 01:00 ET
|
INNATE PHARMA
Marseille, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2021 financial calendar: March...
Innate Pharma 2021 Financial Calendar
December 02, 2020 01:00 ET
|
INNATE PHARMA
MARSEILLE, France, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2021 financial calendar:...